特发性肺纤维化的药物发现与开发：挑战与机遇
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities.
作者信息
Cruwys Simon, Hein Peter, Humphries Bob, Black Darcey
机构信息
TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany.
TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany.
出版信息
Drug Discov Today. 2020 Dec;25(12):2277-2283. doi: 10.1016/j.drudis.2020.09.019. Epub 2020 Sep 30.
PMID:33010480
Abstract
The pharmacological and adverse effect profiles of the two approved therapies for IPF make the development of new therapies challenging. Considering the similarity of the characteristics of drug candidates to Standard of Care is important in defining positioning and development strategies for this disease.
摘要
两种已获批的特发性肺纤维化（IPF）治疗方法的药理特性和不良反应情况使得开发新疗法具有挑战性。在确定该疾病的定位和开发策略时，考虑候选药物特性与标准治疗的相似性很重要。
Zotero 插件